The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.

Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient ...

In sharp contrast to many other cancer types, the incidence and mortality of endometrial cancer continue to grow. This unfortunate trend is, in no small part, a result of the worldwide obesity ...

The guideline aims to optimize health and quality of life for the post-treatment prostate cancer survivor by comprehensively addressing components of follow-up care, including health promotion, ...

Role of adjuvant chemotherapy in patients with stage II-III ampullary cancer.

Lymphedema After Breast Cancer: Incidence, Risk Factors, and Effect on Upper Body Function In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more ...

Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma. This is an ASCO Meeting ...

Comparing the prevalence of non-AIDS defining cancers by HIV status in the Ohio Medicaid population. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not ...

Purpose To update guidance for health care providers about fertility preservation for adults and children with cancer. Methods A systematic review of the literature published from March 2006 through ...

This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.

KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested ...

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers. Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint ...